2026 Global: Benign Prostatic Hyperplasia (Bph) Treatment Devices Market -Competitive Review (2032) report
Description
The 2026 Global: Benign Prostatic Hyperplasia (Bph) Treatment Devices Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Boston Scientific Corporation, headquartered in Marlborough, United States, is a global medical device leader with a deep portfolio for BPH management, including the Rezūm water vapor therapy system. Teleflex Incorporated, based in Wayne, United States, markets the UroLift system, a minimally invasive urethral suspension option that avoids tissue ablation. Olympus Corporation, headquartered in Tokyo, Japan, supplies extensive endoscopic platforms, rigid and flexible scopes, and laser-assisted tools used across BPH procedures. Lumenis Ltd., based in Yokneam Illit, Israel, develops laser systems and energy-based devices adopted for prostatic tissue modification. Karl Storz SE & Co. KG, headquartered in Tuttlingen, Germany, supplies endoscopic equipment, instrument sets, and visualization systems foundational to TURP and related interventions. These five firms form core supply lines that shape access to surgical and minimally invasive BPH therapies worldwide. Their collaborations with clinicians steer device development, regulatory approvals, and market adoption in diverse health systems across regions and specialties.
Stryker Corporation, headquartered in Kalamazoo, United States, contributes advanced urology devices and surgical instruments that complement laser and energy-based BPH therapies. Cook Medical, based in Bloomington, United States, provides minimally invasive delivery systems, catheters, and optics central to catheter-assisted prostatic interventions and TURP adjuncts. Merit Medical Systems, headquartered in South Jordan, United States, supplies disposable instrumentation, guidance catheters, and access devices used in cystoscopic and endourological BPH procedures. Coloplast A/S, headquartered in Humlebæk, Denmark, brings catheter and stent technologies that support urinary tract access and postoperative care following BPH treatments. Medtronic plc, headquartered in Dublin, Ireland, offers a broad range of urology devices and energy-based platforms, leveraging global distribution networks to introduce new BPH therapies alongside established laser systems. Collectively, these firms shape procedural choices, availability of options, and patient access across hospital settings, ambulatory centers, and emerging markets. Their strategic research investments drive durability, safety, and clinician adoption globally.
Across the BPH treatment devices market, leadership is distributed across North America, Europe, and the Middle East, with headquarters spanning the United States, Israel, Japan, Denmark, Germany, and Ireland. The combined footprint enables near-continuous innovation, clinical trials, and regulatory submissions for urology devices, from laser platforms to minimally invasive implants. These firms maintain extensive global manufacturing and distribution networks that translate research into accessible therapies in diverse health systems. Through partnerships with hospitals, professional societies, and training centers, they influence procedural guidelines, reimbursement pathways, and postmarket surveillance. While competition centers on safety, durability, and ease of use, the market also rewards integration of devices and software that streamline patient selection, real-time monitoring, and outcome tracking. In sum, the ten companies identified collectively sustain a dynamic ecosystem driving expanded access to modern BPH therapies and enabling clinicians to tailor interventions to patient needs and resource constraints in an evolving global marketplace.
Boston Scientific Corporation, headquartered in Marlborough, United States, is a global medical device leader with a deep portfolio for BPH management, including the Rezūm water vapor therapy system. Teleflex Incorporated, based in Wayne, United States, markets the UroLift system, a minimally invasive urethral suspension option that avoids tissue ablation. Olympus Corporation, headquartered in Tokyo, Japan, supplies extensive endoscopic platforms, rigid and flexible scopes, and laser-assisted tools used across BPH procedures. Lumenis Ltd., based in Yokneam Illit, Israel, develops laser systems and energy-based devices adopted for prostatic tissue modification. Karl Storz SE & Co. KG, headquartered in Tuttlingen, Germany, supplies endoscopic equipment, instrument sets, and visualization systems foundational to TURP and related interventions. These five firms form core supply lines that shape access to surgical and minimally invasive BPH therapies worldwide. Their collaborations with clinicians steer device development, regulatory approvals, and market adoption in diverse health systems across regions and specialties.
Stryker Corporation, headquartered in Kalamazoo, United States, contributes advanced urology devices and surgical instruments that complement laser and energy-based BPH therapies. Cook Medical, based in Bloomington, United States, provides minimally invasive delivery systems, catheters, and optics central to catheter-assisted prostatic interventions and TURP adjuncts. Merit Medical Systems, headquartered in South Jordan, United States, supplies disposable instrumentation, guidance catheters, and access devices used in cystoscopic and endourological BPH procedures. Coloplast A/S, headquartered in Humlebæk, Denmark, brings catheter and stent technologies that support urinary tract access and postoperative care following BPH treatments. Medtronic plc, headquartered in Dublin, Ireland, offers a broad range of urology devices and energy-based platforms, leveraging global distribution networks to introduce new BPH therapies alongside established laser systems. Collectively, these firms shape procedural choices, availability of options, and patient access across hospital settings, ambulatory centers, and emerging markets. Their strategic research investments drive durability, safety, and clinician adoption globally.
Across the BPH treatment devices market, leadership is distributed across North America, Europe, and the Middle East, with headquarters spanning the United States, Israel, Japan, Denmark, Germany, and Ireland. The combined footprint enables near-continuous innovation, clinical trials, and regulatory submissions for urology devices, from laser platforms to minimally invasive implants. These firms maintain extensive global manufacturing and distribution networks that translate research into accessible therapies in diverse health systems. Through partnerships with hospitals, professional societies, and training centers, they influence procedural guidelines, reimbursement pathways, and postmarket surveillance. While competition centers on safety, durability, and ease of use, the market also rewards integration of devices and software that streamline patient selection, real-time monitoring, and outcome tracking. In sum, the ten companies identified collectively sustain a dynamic ecosystem driving expanded access to modern BPH therapies and enabling clinicians to tailor interventions to patient needs and resource constraints in an evolving global marketplace.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
